Market Cap 18.91M
Revenue (ttm) 15.03M
Net Income (ttm) -11.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.12%
Debt to Equity Ratio 1.73
Volume 72,113
Avg Vol 318,682
Day's Range N/A - N/A
Shares Out 7.51M
Stochastic %K 29%
Beta 6.87
Analysts Hold
Price Target $5.25

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children....

Industry: Medical Devices
Sector: Healthcare
Phone: 844 672 4357
Address:
7921 Southpark Plaza, Suite 210, Littleton, United States
Giovannirs3
Giovannirs3 Nov. 14 at 10:48 PM
$VVOS 👇
0 · Reply
oklnd
oklnd Nov. 14 at 10:30 PM
$VVOS 5 months of zero trading lol .
0 · Reply
Mad_Macks
Mad_Macks Nov. 14 at 10:28 PM
$VVOS accounting closing the books
0 · Reply
JohnnyBean
JohnnyBean Nov. 14 at 9:10 PM
$VVOS The good and the bad: "The Company anticipates that its revenue increased by over 50% for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The primary cause was due to an increase in sales of Vivos products and services that originated from the Company’s newly acquired subsidiary SCN. The Company also anticipates that its Sales, General and Administrative expenses also increased by over 50% for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The primary cause of this increase was due to increase of salaries and wages, rent and other expenses associated with SCN’s operations. As a result, the Company anticipates an increase in its net loss for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The figures reported above are still under review and may differ once reported in the Form 10-Q to be filed by the Registrant."
1 · Reply
Giovannirs3
Giovannirs3 Nov. 14 at 9:08 PM
$VVOS 👇
0 · Reply
JohnnyBean
JohnnyBean Nov. 14 at 9:08 PM
$VVOS "currently expects to file the Form 10-Q within the five-day extension period provided"
0 · Reply
GamblerDan
GamblerDan Nov. 14 at 9:04 PM
$VVOS https://www.sec.gov/Archives/edgar/data/1716166/000149315225023404/formnt10-q.htm
1 · Reply
apple9
apple9 Nov. 14 at 8:53 PM
$VVOS huntsman has to have some positive news to release with earnings 
1 · Reply
Giovannirs3
Giovannirs3 Nov. 14 at 8:28 PM
$VVOS ❤️👆👇👌🤗🤣👍
0 · Reply
JohnnyBean
JohnnyBean Nov. 14 at 6:37 PM
$VVOS Perhaps my first thought from Nov. 7th was right?
1 · Reply
Latest News on VVOS
Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript

Aug 22, 2025, 3:08 PM EDT - 3 months ago

Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript


Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:31 PM EDT - 6 months ago

Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript


Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 12:18 AM EDT - 8 months ago

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript


Vivos Therapeutics Closes $4 Million Private Placement

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Closes $4 Million Private Placement


Vivos Therapeutics Announces Reverse Stock Split

Oct 26, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Reverse Stock Split


Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine


Giovannirs3
Giovannirs3 Nov. 14 at 10:48 PM
$VVOS 👇
0 · Reply
oklnd
oklnd Nov. 14 at 10:30 PM
$VVOS 5 months of zero trading lol .
0 · Reply
Mad_Macks
Mad_Macks Nov. 14 at 10:28 PM
$VVOS accounting closing the books
0 · Reply
JohnnyBean
JohnnyBean Nov. 14 at 9:10 PM
$VVOS The good and the bad: "The Company anticipates that its revenue increased by over 50% for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The primary cause was due to an increase in sales of Vivos products and services that originated from the Company’s newly acquired subsidiary SCN. The Company also anticipates that its Sales, General and Administrative expenses also increased by over 50% for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The primary cause of this increase was due to increase of salaries and wages, rent and other expenses associated with SCN’s operations. As a result, the Company anticipates an increase in its net loss for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The figures reported above are still under review and may differ once reported in the Form 10-Q to be filed by the Registrant."
1 · Reply
Giovannirs3
Giovannirs3 Nov. 14 at 9:08 PM
$VVOS 👇
0 · Reply
JohnnyBean
JohnnyBean Nov. 14 at 9:08 PM
$VVOS "currently expects to file the Form 10-Q within the five-day extension period provided"
0 · Reply
GamblerDan
GamblerDan Nov. 14 at 9:04 PM
$VVOS https://www.sec.gov/Archives/edgar/data/1716166/000149315225023404/formnt10-q.htm
1 · Reply
apple9
apple9 Nov. 14 at 8:53 PM
$VVOS huntsman has to have some positive news to release with earnings 
1 · Reply
Giovannirs3
Giovannirs3 Nov. 14 at 8:28 PM
$VVOS ❤️👆👇👌🤗🤣👍
0 · Reply
JohnnyBean
JohnnyBean Nov. 14 at 6:37 PM
$VVOS Perhaps my first thought from Nov. 7th was right?
1 · Reply
Bumpkaboo
Bumpkaboo Nov. 14 at 6:28 PM
$VVOS where is your Losses Release?
0 · Reply
oklnd
oklnd Nov. 14 at 5:11 PM
$VVOS big sellings omg
0 · Reply
oklnd
oklnd Nov. 14 at 3:46 PM
$VVOS blood will happen once they release the earnings lower low 1.8
0 · Reply
Moneyybaggs
Moneyybaggs Nov. 14 at 3:13 PM
$VVOS Hopefully your capitulation just called the bottom @yachtbound.
1 · Reply
yachtbound
yachtbound Nov. 14 at 2:58 PM
$VVOS out!
0 · Reply
Giovannirs3
Giovannirs3 Nov. 14 at 1:05 PM
0 · Reply
oklnd
oklnd Nov. 14 at 12:24 PM
$VVOS worth to trade between $0.40 to $0.60. Believe will happen very soon.
0 · Reply
Maissessap
Maissessap Nov. 14 at 9:38 AM
$VVOS Huntsman, where is the promised free cash flow???
0 · Reply
Are_You_Experienced
Are_You_Experienced Nov. 13 at 7:50 PM
$VVOS Blocked
0 · Reply
Creyedr
Creyedr Nov. 13 at 7:25 PM
$VVOS anemic volume, don't get shaken out...hold your shares.
0 · Reply
Tradelyfe
Tradelyfe Nov. 13 at 7:19 PM
$VVOS $2…very soon
0 · Reply
Moneyybaggs
Moneyybaggs Nov. 13 at 6:38 PM
$VVOS Looks like another delay for releasing 3Q earnings. Just not a good look for the leadership team.
0 · Reply